GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Gross Margin %

Can Fite Biofarma (Can Fite Biofarma) Gross Margin %

: 0.00% (As of Dec. 2023)
View and export this data going back to 2012. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Can Fite Biofarma's Gross Profit for the three months ended in Dec. 2023 was $0.16 Mil. Can Fite Biofarma's Revenue for the three months ended in Dec. 2023 was $0.16 Mil. Therefore, Can Fite Biofarma's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Can Fite Biofarma's Gross Margin % or its related term are showing as below:


CANF's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.4
* Ranked among companies with meaningful Gross Margin % only.

Can Fite Biofarma had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Can Fite Biofarma was 0.00% per year.


Can Fite Biofarma Gross Margin % Historical Data

The historical data trend for Can Fite Biofarma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Can Fite Biofarma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma Gross Margin % Distribution

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Gross Margin % falls into.



Can Fite Biofarma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Can Fite Biofarma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0.7 / 0.743
=(Revenue - Cost of Goods Sold) / Revenue
=(0.743 - 0) / 0.743
=N/A %

Can Fite Biofarma's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.2 / 0.155
=(Revenue - Cost of Goods Sold) / Revenue
=(0.155 - 0) / 0.155
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Can Fite Biofarma  (AMEX:CANF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Can Fite Biofarma had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Can Fite Biofarma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019